NCT03835013 (COCOA) is a NA clinical trial of Saline 0.9% in Cardiovascular Diseases, sponsored by Cambridge University Hospitals NHS Foundation Trust.

Who is sponsoring NCT03835013?

NCT03835013 is sponsored by Cambridge University Hospitals NHS Foundation Trust.

What drugs are being tested in NCT03835013?

Interventions in NCT03835013: Saline 0.9%, Glucagon (25ng/kg/min), Glucagon (50ng/kg/min), Exenatide.

What condition does NCT03835013 study?

NCT03835013 studies Cardiovascular Diseases.

Is NCT03835013 still recruiting?

NCT03835013 is currently completed. Last updated 3 April 2024.

Last reviewed 2024-04-03 · How we verify

NCT03835013: COCOA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

Completed NA Last updated 3 April 2024

What this trial tests

NA trial testing Saline 0.9% in Cardiovascular Diseases in 26 participants. Completed in 1 November 2021.

Timeline

11 February 2019

Primary endpoint
1 November 2021

1 November 2021

Quick facts

Lead sponsor	Cambridge University Hospitals NHS Foundation Trust
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	basic science
Enrollment	26
Start date	11 February 2019
Primary completion	1 November 2021
Estimated completion	1 November 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

Saline 0.9% — full drug profile →
Glucagon (25ng/kg/min) — full drug profile →
Glucagon (50ng/kg/min) — full drug profile →
Exenatide (EXENATIDE) — full drug profile →

Conditions studied

Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Who can join

Adults 18 to 40, male only, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors, GLP-1 and glucagon. Glucagon, exenatide and 0.9% saline will be intravenously infused, both in isolation, and combination into healthy male participants. Overall, the aim of the study is to further our understanding on the role these endogenous substances play (both in isolation and combination) in haemodynamic regulation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon-like peptide-1 and glucagon receptor in healthy subjects.
Goodman J, Parker VE, McEniery CM, Di Stefano G, et al · · 2026 · cited 1× · PMID 41025322 · DOI 10.1002/bcp.70282

Verify or expand the search:

Other trials of Saline 0.9%

Trials testing the same drug.

NCT06966674 — No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track · NA · recruiting
NCT06966518 — Intraoperative Combination of Ketamine and Magnesium Sulfate Infusions on Postoperative Analgesia in Open Rhinoplasty · NA · recruiting
NCT06823349 — Comparative Analysis of Analgesic Efficacy: by Single Shot Intrathecal Analgesia (SSSA) in Normal Labor · Phase 4 · recruiting
NCT06406010 — Investigating the Effect of Pericapsular Nerve Group (PENG) Block on Postoperative Pain After Peri-acetabular Osteotomy · Phase 4 · recruiting
NCT06443255 — Cocaine, Lidocaine/xylometazoline and Saline for Nasal Analgesia · Phase 3 · completed

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
NCT07426263 — Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation. · NA · active not recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Cambridge University Hospitals NHS Foundation Trust trials

Trials by the same sponsor.

NCT07516496 — Metabolic Phenotyping in vEDS · recruiting
NCT07129577 — Point of Care Testing in Emergency Departments After Mild Traumatic Brain Injury · not yet recruiting
NCT05093231 — Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06555757 — Utilising AI Analysis of Sounds To prEdict heaRt failurE decOmpensation · not yet recruiting
NCT06427694 — Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03835013 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cambridge University Hospitals NHS Foundation Trust
Last refreshed: 3 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03835013.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing